





抗体薬物複合体(システイン結合型 ADCミミック)

Antibody drug conjugate (Cysteine-conjugated ADC mimic)

V200204E

Mobile phase containing TFA

Mobile phase containing formic acid





Method of reduction

ADC (1.25 mg/mL)
or mAb (2.0 mg/mL)
20 μ L

← 20 mM DTT 20 μ L

30°C, 60 min

HPLC analysis



Column	: YMC-Triart Bio C4 (1.9 μ m, 30 nm) 50 X 2.1 mm I.D.
Eluent <TFA>	: A) water/TFA (100/0.1) B) acetonitrile/TFA (100/0.1) 27-42%B (0-10 min), 90%B (10-12.5 min)
Eluent <Formic acid>	: A) water/formic acid (100/0.1) B) acetonitrile/formic acid (100/0.1) 22-37%B (0-10 min), 90%B (10-12.5 min)
Flow rate	: 0.4 mL/min
Temperature	: 80°C
Detection	: UV at 280 nm
Injection	: 2 μ L for reduced mAb, 4 μ L for reduced ADC-mimic